NO20050309L - Nye komplekser av fettsyreestere av polyhydroksyalkan- og pyridinkarboksyderivater - Google Patents

Nye komplekser av fettsyreestere av polyhydroksyalkan- og pyridinkarboksyderivater

Info

Publication number
NO20050309L
NO20050309L NO20050309A NO20050309A NO20050309L NO 20050309 L NO20050309 L NO 20050309L NO 20050309 A NO20050309 A NO 20050309A NO 20050309 A NO20050309 A NO 20050309A NO 20050309 L NO20050309 L NO 20050309L
Authority
NO
Norway
Prior art keywords
derivatives
fatty acid
pyridinecarboxy
acid esters
polyhydroxyalkane
Prior art date
Application number
NO20050309A
Other languages
English (en)
Other versions
NO334647B1 (no
Inventor
Morten Sloth Weidner
Original Assignee
Astion Dermatology As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30001772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20050309(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astion Dermatology As filed Critical Astion Dermatology As
Publication of NO20050309L publication Critical patent/NO20050309L/no
Publication of NO334647B1 publication Critical patent/NO334647B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

J Den foreliggende oppfinnelse vedrører nye kombinasjoner av fettsyrederivater og pyridinkarboksyderivater, som inkluderer fettsyreestere med glyserol og 3-karboksypyridinderivater så som niacinamid. Slike kombinasjoner har overraskende vist antiviral og antimikrobiell aktivitet og anvendelsen for behandling av inflammatoriske tilstander og infeksjoner beskrives her. --------------- - ----- ---- -- - --- -- ---- -------- 7@ 7-. 7'-
NO20050309A 2002-06-20 2005-01-19 Nye komplekser av fettsyreestere av polyhydroksyalkaner og pyridinkarboksyderivater NO334647B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38987902P 2002-06-20 2002-06-20
DKPA200200951 2002-06-20
PCT/DK2003/000423 WO2004000333A1 (en) 2002-06-20 2003-06-20 Novel complexes of fatty acid esters of polyhydroxyalkanes and pyridine carboxy derivatives

Publications (2)

Publication Number Publication Date
NO20050309L true NO20050309L (no) 2005-03-18
NO334647B1 NO334647B1 (no) 2014-05-05

Family

ID=30001772

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050309A NO334647B1 (no) 2002-06-20 2005-01-19 Nye komplekser av fettsyreestere av polyhydroksyalkaner og pyridinkarboksyderivater

Country Status (20)

Country Link
US (2) US8084049B2 (no)
EP (2) EP1640011A1 (no)
JP (1) JP4589721B2 (no)
KR (1) KR100983802B1 (no)
CN (1) CN1674921A (no)
AT (1) ATE341334T1 (no)
AU (1) AU2003240441B2 (no)
CA (1) CA2491871C (no)
CY (1) CY1105902T1 (no)
DE (1) DE60308891T2 (no)
DK (1) DK1560589T3 (no)
EA (1) EA008023B1 (no)
ES (1) ES2274236T3 (no)
HK (1) HK1076395A1 (no)
NO (1) NO334647B1 (no)
NZ (1) NZ537783A (no)
PL (1) PL213646B1 (no)
PT (1) PT1560589E (no)
SI (1) SI1560589T1 (no)
WO (1) WO2004000333A1 (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964297B1 (en) * 1998-07-14 2005-11-15 L & M Radiator, Inc. Removable tube heat exchanger and header plate
US8383653B2 (en) 2003-07-02 2013-02-26 Albert Einstein College Of Medicine Of Yeshiva University SIR2 regulation
GB0425658D0 (en) * 2004-11-22 2004-12-22 Stanford Rook Ltd Immunotherapeutic agent
FR2894142B1 (fr) * 2005-12-05 2009-06-12 Oreal Utilisation de l'association du dipeptide tyrosine-arginine et de la niacimanide en tant qu'antagoniste de substance p
US8858968B2 (en) 2005-12-05 2014-10-14 L'oreal Use of tyrosine-arginine dipeptide and niacinamide as substance P antagonist
EP1864657A1 (en) * 2006-06-08 2007-12-12 Astion Pharma A/S Treatment of cutaneous neurogenic inflammation
US8816110B2 (en) 2007-02-15 2014-08-26 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
ES2561482T3 (es) * 2007-02-15 2016-02-26 Centre De Recherche Sur Les Biotechnologies Marine Monoglicéridos de ácido graso poliinsaturado, derivados, y sus usos
CA2677670C (en) 2007-03-20 2010-08-03 Centre De Recherche Sur Les Biotechnologies Marines Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
WO2010002586A2 (en) * 2008-06-30 2010-01-07 Elc Management Llc Topical compositions comprising isonicotinamide
JP2010126472A (ja) * 2008-11-27 2010-06-10 Marubeni Nisshin Feed Co Ltd クロストリジウム症の予防及び／又は治療用飼料
US20110097770A1 (en) * 2009-10-27 2011-04-28 Dr. Chifu Huang Novel method to generate bioactive compounds in algae
WO2011133692A1 (en) * 2010-04-20 2011-10-27 Cedars-Sinai Medical Center Boosting immune defense by upregulating ccaat/enhancer binding protein epsilon
JP5726481B2 (ja) * 2010-10-29 2015-06-03 日本精化株式会社 ヒドロキシニコチン酸又はその誘導体を含有する化粧料又は皮膚外用剤
AU2011345226B2 (en) 2010-12-23 2014-11-13 Hill's Pet Nutrition, Inc. Pet food compositions and methods for treating arthritis and inflammation associated with arthritis
CA2928962A1 (en) 2013-10-28 2015-05-07 Morten SLOTH WEIDNER Dermatological compositions
US9447020B2 (en) 2013-10-31 2016-09-20 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
CN105001228B (zh) * 2015-07-17 2017-03-22 福建省肿瘤医院 源于桔青霉的penicitrinine A在制备抗人口腔表皮样瘤药物中的应用
CN105061445B (zh) * 2015-07-17 2017-04-26 福建省肿瘤医院 源于桔青霉的penicitrinine A及其制备抗人胃癌药物的应用
CN105061446B (zh) * 2015-07-17 2017-04-26 福建省肿瘤医院 源于桔青霉的penicitrinine A及在制备抗鼻咽癌药物上的应用
CN105061444B (zh) * 2015-07-17 2017-04-26 福建省肿瘤医院 源于桔青霉的penicitrinine A及其制备抗人结直肠癌药物的应用
CN105153176B (zh) * 2015-07-17 2017-06-06 福建省肿瘤医院 源于桔青霉的penicitrinine A及其制备抗人肺癌药物的应用
MX2018004143A (es) 2015-10-05 2018-06-13 Unilever Nv Composicion que comprende niacinamida y picolinamida.
CN106749211B (zh) * 2016-11-22 2019-08-09 斯芬克司药物研发（天津）股份有限公司 一种烟酸酯及其制备方法与应用
CN106854204B (zh) * 2016-11-22 2019-10-08 斯芬克司药物研发（天津）股份有限公司 一种烟酸脂化合物及其制备方法与应用
CN106749210B (zh) * 2016-11-22 2019-08-09 斯芬克司药物研发（天津）股份有限公司 一种烟酸酯类化合物及其制备方法与应用
WO2019153073A1 (en) 2018-02-07 2019-08-15 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof
CN112384212A (zh) 2018-05-03 2021-02-19 Scf制药股份有限公司 多不饱和脂肪酸单甘油酯、其组合物、方法和用途
WO2021043719A1 (fr) * 2019-09-03 2021-03-11 Universite De Picardie Jules Verne Composition pharmaceutique antivirale contenant du thionicotinamide
CN113197897A (zh) * 2021-04-29 2021-08-03 四川大学 烟酰胺在制备变异链球菌产酸和生物膜形成抑制剂的应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3676556A (en) * 1969-09-26 1972-07-11 Hoffmann La Roche Method of stabilizing nialinamide against caking
US4002775A (en) * 1973-07-09 1977-01-11 Kabara Jon J Fatty acids and derivatives of antimicrobial agents
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5231087A (en) * 1988-03-16 1993-07-27 Cellegy Pharmaceuticals, Inc. Treatment of skin diseases and tumors with esters and amides of monocarboxylic acids
JP2848830B2 (ja) * 1988-09-02 1999-01-20 旭電化工業株式会社 水に難溶性の脂肪酸エステルの可溶化方法
FI912955A (fi) * 1990-06-25 1991-12-26 Res Found Mental Hygiene Antimikroba fettsyrasammansaettningar.
AU668559B2 (en) * 1992-06-03 1996-05-09 Unilever Plc Improvements relating to cosmetic compositions
DE4234188C2 (de) * 1992-10-10 1996-01-11 Beiersdorf Ag Antimycotische kosmetische und dermatologische Verwendungen
JPH06245719A (ja) * 1993-02-19 1994-09-06 Nippon Oil & Fats Co Ltd 粉末乳化剤および製造方法
DE4337711A1 (de) * 1993-11-05 1995-05-11 Beiersdorf Ag Gegen unreine Haut und milde Formen der Akne wirksame Zubereitungen mit einem Gehalt an Monocarbonsäuremonoglyceriden kurzer und mittellanger Fettsäuren
US6087391A (en) * 1994-03-14 2000-07-11 Weidner; Morten Sloth Method of rendering organic compounds soluble in fatty systems, novel chemical complexes of such compounds and various applications of the complexes
DE4434775A1 (de) * 1994-09-29 1996-04-04 Beiersdorf Ag Dermatologische Zubereitungen mit einem Gehalt an Fettsäureglyceriden gegen Superinfektionen
DE4434781A1 (de) * 1994-09-29 1996-04-04 Beiersdorf Ag Verwendung von Fettsäureestern zur Bekämpfung von Superinfektionen
DE4438588A1 (de) * 1994-10-28 1996-05-02 Beiersdorf Ag Gegen unreine Haut, leichte Formen der Akne sowie Propionibacterium acnes wirksame Wirkstoffkombinationen auf der Basis von Wollwachssäuren und Glycerinestern gesättigter Fettsäuren
DK0823897T3 (da) * 1995-05-01 2004-12-06 Scarista Ltd Nicotinsyreestere og farmaceutiske præparater indeholdende disse
JP3585306B2 (ja) * 1996-01-16 2004-11-04 エーザイ株式会社 防腐防黴剤
US6248763B1 (en) * 1998-05-19 2001-06-19 Scivoletto Rosemarie Composition for treating skin conditions
CN1160053C (zh) * 1999-05-25 2004-08-04 宝洁公司 低粘滞性的烟酰胺组合物
JP3530075B2 (ja) * 1999-06-07 2004-05-24 三菱化学フーズ株式会社 乳化剤組成物
GB9916536D0 (en) 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
JP2001078735A (ja) * 1999-09-09 2001-03-27 Yakult Honsha Co Ltd 乳化剤含有飲食品
JP2001128644A (ja) * 1999-11-05 2001-05-15 Takeda Chem Ind Ltd 固形状食品組成物
IL133976A (en) 2000-01-11 2006-09-05 Dermipsor Ltd Agents for the treatment of skin disorders
JP2003529590A (ja) 2000-03-21 2003-10-07 アスション デヴェロップメント エーピーエス ピリジンカルボキシ誘導体およびｈ２ヒスタミン受容体アンタゴニストからなる化学的複合体
WO2001074781A1 (en) 2000-03-21 2001-10-11 Astion Development Aps Chemical complex comprising a substituted pyridine carboxy derivative and a glucosaminoglycan
JP4921630B2 (ja) * 2000-05-10 2012-04-25 小川香料株式会社 ビタミン臭抑制剤
WO2001091704A1 (en) * 2000-06-01 2001-12-06 The Procter & Gamble Company Water-in-oil emulsified make-up composition
WO2002005850A2 (en) 2000-07-19 2002-01-24 Pitmy International N.V. Enhancement of the action of anti-infective agents
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases

Also Published As

Publication number Publication date
DE60308891T2 (de) 2007-05-24
CA2491871C (en) 2011-01-04
CA2491871A1 (en) 2003-12-31
HK1076395A1 (en) 2006-01-20
NZ537783A (en) 2006-12-22
US8084049B2 (en) 2011-12-27
AU2003240441B2 (en) 2008-09-18
ES2274236T3 (es) 2007-05-16
US20060069131A1 (en) 2006-03-30
ATE341334T1 (de) 2006-10-15
NO334647B1 (no) 2014-05-05
DK1560589T3 (da) 2007-02-12
AU2003240441A1 (en) 2004-01-06
DE60308891D1 (de) 2006-11-16
US20120142744A1 (en) 2012-06-07
CN1674921A (zh) 2005-09-28
WO2004000333A1 (en) 2003-12-31
EA008023B1 (ru) 2007-02-27
KR20050024356A (ko) 2005-03-10
PT1560589E (pt) 2007-01-31
SI1560589T1 (sl) 2007-02-28
JP4589721B2 (ja) 2010-12-01
PL375204A1 (en) 2005-11-28
PL213646B1 (pl) 2013-04-30
EA200401600A1 (ru) 2005-12-29
KR100983802B1 (ko) 2010-09-27
EP1560589B1 (en) 2006-10-04
JP2005537238A (ja) 2005-12-08
EP1640011A1 (en) 2006-03-29
CY1105902T1 (el) 2011-02-02
EP1560589A1 (en) 2005-08-10

Similar Documents

Publication Publication Date Title
NO20050309L (no) Nye komplekser av fettsyreestere av polyhydroksyalkan- og pyridinkarboksyderivater
NO20056007L (no) Dobbel NK1/NK3 antagonister for behandling av schizofreni
TW200716661A (en) A novel triterpenic acid derivative and the skin external preparation containing the same
DK1942108T3 (da) Forbindelse indeholdende basisk gruppe samt anvendelse deraf
ATE245152T1 (de) Dioxocyclopentylhydroxamsäure
EA200801134A1 (ru) Замещенные бициклические пиримидоновые производные
BG106825A (en) Substituted oxazolidinones and their use in the field of blood coagulation
DK1725536T3 (da) Imidazolin-derivater med CB1-antagonistisk aktivitet
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
NO20070445L (no) Pyrimidinderivater.
ATE305777T1 (de) Mittel zur verhinderung der chronischen abstossreaktion infolge einer organtransplantation
CA3156303A1 (en) 5-FLUORONICOTINAMIDE DERIVATIVES AND THEIR USES
MX2020000576A (es) Compuestos quimicos.
BG108498A (en) New derivatives of oxazolidinones as antibacterial agents
DE69729213D1 (de) Tricyclische aminderivate
NO20055517L (no) 4-,6-O 7-hydroksyindoler med N-oksidgrupper og anvendelse av disse som terapeutiske midler
UA91549C2 (ru) Производные хинолина как антибактериальные агенты
DE50001301D1 (de) Behandlung der migräne durch verabreichung von alpha-liponsäure oder derivaten derselben
NO20070421L (no) Radiosensitiviserende middel
TW200700421A (en) Novel triazolopyrimidine derivatives
ATE325809T1 (de) Amidderivate der 2-amino-3-hydroxy-4-tert-leucyl- amino-5-phenyl-pentansäure
ATE315038T1 (de) Antibakterielle mittel
NO20055699L (no) Imidazopyridinintermediater
MX2024003015A (es) Nuevos derivados de quinolina.
MX2023001649A (es) Derivados de amida hibrida de anfotericina b.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: CIPHER PHARMACEUTICALS INC, CA

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ASTION PHARMA A/S, DK

CREP Change of representative

Representative=s name: VALUA APS, BORGMESTER JENSENS ALLE 25C, 1. SAL, 2100

MM1K Lapsed by not paying the annual fees